Profil
Adrian J.
Hepner served as Senior Medical Director at UCB Biosciences, Inc. from 2012 to 2013, Vice President-Clinical Research at Avanir Pharmaceuticals, Inc. from 2006 to 2012, VP-Clinical Research & Medical Affairs at BioDelivery Sciences International, Inc. from 2013 to 2014, Chief Medical Officer & Executive Vice President at Eagle Pharmaceuticals, Inc. from 2016 to 2020, Chief Medical Officer at Pharnext SA from 2020 to 2022, and currently serves as President & Chief Medical Officer at Coya Therapeutics, Inc. Hepner received his graduate and doctorate degrees from Universidad de Buenos Aires in 1986 and 1983, respectively.
Anciens postes connus de Adrian Hepner
| Sociétés | Poste | Fin |
|---|---|---|
| COYA THERAPEUTICS, INC. | President | 17/07/2023 |
| PHARNEXT SCA | Chief Tech/Sci/R&D Officer | 01/01/2022 |
| EAGLE PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 31/07/2020 |
| BIODELIVERY SCIENCES INTERNATIONAL, INC. | Chief Tech/Sci/R&D Officer | 01/12/2014 |
| UCB BioSciences, Inc. | Corporate Officer/Principal | 01/01/2013 |
Formation de Adrian Hepner
| Universidad de Buenos Aires | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| EAGLE PHARMACEUTICALS, INC. | Health Technology |
| PHARNEXT SCA | Health Technology |
| COYA THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Avanir Pharmaceuticals, Inc.
 Avanir Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Avanir Pharmaceuticals, Inc. engages in the development of therapeutic products for the treatment of nervous system disorder. The company was founded on August 31, 1988 and headquartered in Aliso Viejo, CA. | Health Technology |
BioDelivery Sciences International, Inc.
 BioDelivery Sciences International, Inc. Pharmaceuticals: MajorHealth Technology BioDelivery Sciences International, Inc. operates as a pharmaceutical company engaged in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. Its products include Symproic and Belbuca. The company was founded on January 6, 1997 and is headquartered in Raleigh, NC. | Health Technology |
| UCB BioSciences, Inc. |
